Focal adhesion kinase-mediated activation of glycogen synthase kinase 3β regulates IL-33 receptor internalization and IL-33 signaling

Journal of Immunology

Volumn 194, Issue 2, 2015, Pages 795-802

  Zhao, Jing ^a   Wei, Jianxin ^a   Bowser, Rachel K ^a   Traister, Russell S ^a   Fan, Ming Hui ^a   Zhao, Yutong ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE RECEPTOR; FOCAL ADHESION KINASE; GLYCOGEN SYNTHASE KINASE 3BETA; LONG FORM ST2 RECEPTOR; UNCLASSIFIED DRUG; FOCAL ADHESION KINASE 1; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; IL33 PROTEIN, MOUSE; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 33; INTERLEUKIN DERIVATIVE; PROTEIN BINDING; PTK2 PROTEIN, MOUSE; ST2L PROTEIN, MOUSE;

ANIMAL TISSUE; ARTICLE; BINDING SITE; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME BINDING; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; INTERNALIZATION; LUNG ALVEOLUS EPITHELIUM CELL; MOUSE; NONHUMAN; PNEUMONIA; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; SIGNAL TRANSDUCTION; AMINO ACID SUBSTITUTION; ANIMAL; CELL LINE; GENETICS; IMMUNOLOGY; MISSENSE MUTATION;

AMINO ACID SUBSTITUTION; ANIMALS; BINDING SITES; CELL LINE; ENZYME ACTIVATION; FOCAL ADHESION KINASE 1; GLYCOGEN SYNTHASE KINASE 3; INTERLEUKIN-33; INTERLEUKINS; MICE; MUTATION, MISSENSE; PROTEIN BINDING; RECEPTORS, INTERLEUKIN-1; SIGNAL TRANSDUCTION;

EID: 84920438858     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1401414     Document Type: Article

References (51)

1. Moussion, C., N. Ortega, and J. P. Girard. 2008. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: A novel alarmin? PLoS One 3: e3331.
2. Kouzaki, H., K. Iijima, T. Kobayashi, S. M. O'Grady, and H. Kita. 2011. The danger signal, extracellular ATP, is a sensor for an airborne allergen and triggers IL-33 release and innate Th2-type responses. J. Immunol. 186: 4375-4387.
3. Cayrol, C., and J. P. Girard. 2009. The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. Proc. Natl. Acad. Sci. USA 106: 9021-9026.
4. Lüthi, A. U., S. P. Cullen, E. A. McNeela, P. J. Duriez, I. S. Afonina, C. Sheridan, G. Brumatti, R. C. Taylor, K. Kersse, P. Vandenabeele, et al. 2009. Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. Immunity 31: 84-98.
5. Zhao, J., J. Wei, R. K. Mialki, D. F. Mallampalli, B. B. Chen, T. Coon, C. Zou, R. K. Mallampalli, and Y. Zhao. 2012. F-box protein FBXL19-mediated ubiquitination and degradation of the receptor for IL-33 limits pulmonary inflammation. Nat. Immunol. 13: 651-658.
6. Talabot-Ayer, D., C. Lamacchia, C. Gabay, and G. Palmer. 2009. Interleukin-33 is biologically active independently of caspase-1 cleavage. J. Biol. Chem. 284: 19420-19426.
7. Yagami, A., K. Orihara, H. Morita, K. Futamura, N. Hashimoto, K. Matsumoto, H. Saito, and A. Matsuda. 2010. IL-33 mediates inflammatory responses in human lung tissue cells. J. Immunol. 185: 5743-5750.
8. Hong, Y. J., M. H. Jeong, Y. H. Choi, J. S. Ko, M. G. Lee, W. Y. Kang, S. E. Lee, S. H. Kim, K. H. Park, D. S. Sim, et al. 2009. Positive remodeling is associated with more plaque vulnerability and higher frequency of plaque prolapse accompanied with post-procedural cardiac enzyme elevation compared with intermediate/negative remodeling in patients with acute myocardial infarction. J. Cardiol. 53: 278-287.
9. Choi, Y. S., H. J. Choi, J. K. Min, B. J. Pyun, Y. S. Maeng, H. Park, J. Kim, Y. M. Kim, and Y. G. Kwon. 2009. Interleukin-33 induces angiogenesis and vascular permeability through ST2/TRAF6-mediated endothelial nitric oxide production. Blood 114: 3117-3126.
10. Oboki, K., S. Nakae, K. Matsumoto, and H. Saito. 2011. IL-33 and airway inflammation. Allergy Asthma Immunol. Res. 3: 81-88.
11. Alves-Filho, J. C., F. Sônego, F. O. Souto, A. Freitas, W. A. Verri Jr., M. Auxiliadora-Martins, A. Basile-Filho, A. N. McKenzie, D. Xu, F. Q. Cunha, and F. Y. Liew. 2010. Interleukin-33 attenuates sepsis by enhancing neutrophil influx to the site of infection. Nat. Med. 16: 708-712.
12. Liu, X., M. Li, Y. Wu, Y. Zhou, L. Zeng, and T. Huang. 2009. Anti-IL-33 antibody treatment inhibits airway inflammation in a murine model of allergic asthma. Biochem. Biophys. Res. Commun. 386: 181-185.
13. Yin, H., X. Y. Li, B. H. Yuan, B. B. Zhang, S. L. Hu, H. B. Gu, X. B. Jin, and J. Y. Zhu. 2011. Adenovirus-mediated overexpression of soluble ST2 provides a protective effect on lipopolysaccharide-induced acute lung injury in mice. Clin. Exp. Immunol. 164: 248-255.
14. Kondo, Y., T. Yoshimoto, K. Yasuda, S. Futatsugi-Yumikura, M. Morimoto, N. Hayashi, T. Hoshino, J. Fujimoto, and K. Nakanishi. 2008. Administration of IL-33 induces airway hyperresponsiveness and goblet cell hyperplasia in the lungs in the absence of adaptive immune system. Int. Immunol. 20: 791-800.
15. Li, H., K. Tago, K. Io, K. Kuroiwa, T. Arai, H. Iwahana, S. Tominaga, and K. Yanagisawa. 2000. The cloning and nucleotide sequence of human ST2L cDNA. Genomics 67: 284-290.
16. Trajkovic, V., M. J. Sweet, and D. Xu. 2004. T1/ST2-an IL-1 receptor-like modulator of immune responses. Cytokine Growth Factor Rev. 15: 87-95.
17. Löhning, M., A. Stroehmann, A. J. Coyle, J. L. Grogan, S. Lin, J. C. Gutierrez-Ramos, D. Levinson, A. Radbruch, and T. Kamradt. 1998. T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function. Proc. Natl. Acad. Sci. USA 95: 6930-6935.
18. Sims, J. E., C. J. March, D. Cosman, M. B. Widmer, H. R. MacDonald, C. J. McMahan, C. E. Grubin, J. M. Wignall, J. L. Jackson, S. M. Call, et al. 1988. cDNA expression cloning of the IL-1 receptor, a member of the immunoglobulin superfamily. Science 241: 585-589.
19. Zhao, J., Q. Chen, H. Li, M. Myerburg, E. W. Spannhake, V. Natarajan, and Y. Zhao. 2012. Lysophosphatidic acid increases soluble ST2 expression in mouse lung and human bronchial epithelial cells. Cell. Signal. 24: 77-85.
20. Loberg, R. D., E. Vesely, and F. C. Brosius, III. 2002. Enhanced glycogen synthase kinase-3β activity mediates hypoxia-induced apoptosis of vascular smooth muscle cells and is prevented by glucose transport and metabolism. J. Biol. Chem. 277: 41667-41673.
21. Song, L., P. De Sarno, and R. S. Jope. 2002. Central role of glycogen synthase kinase-3β in endoplasmic reticulum stress-induced caspase-3 activation. J. Biol. Chem. 277: 44701-44708.
22. Dickey, A., S. Schleicher, K. Leahy, R. Hu, D. Hallahan, and D. K. Thotala. 2011. GSK-3β inhibition promotes cell death, apoptosis, and in vivo tumor growth delay in neuroblastoma Neuro-2A cell line. J. Neurooncol. 104: 145-153.
23. Meares, G. P., and R. S. Jope. 2007. Resolution of the nuclear localization mechanism of glycogen synthase kinase-3: functional effects in apoptosis. J. Biol. Chem. 282: 16989-17001.
24. Yost, C., M. Torres, J.R.Miller, E. Huang, D. Kimelman, and R. T. Moon. 1996. The axis-inducing activity, stability, and subcellular distribution of β-catenin is regulated in Xenopus embryos by glycogen synthase kinase 3. Genes Dev. 10: 1443-1454.
25. Lim, J. H., H. Jono, K. Komatsu, C. H.Woo, J. Lee, M.Miyata, T. Matsuno, X. Xu, Y. Huang, W. Zhang, et al. 2012. CYLD negatively regulates transforming growth factor-β-signalling via deubiquitinating Akt. Nat. Commun. 3: 771.
26. Hughes, K., E. Nikolakaki, S. E. Plyte, N. F. Totty, and J. R. Woodgett. 1993. Modulation of the glycogen synthase kinase-3 family by tyrosine phosphorylation. EMBO J. 12: 803-808.
27. Vines, A., S. Cahoon, I. Goldberg, U. Saxena, and S. Pillarisetti. 2006. Novel anti-inflammatory role for glycogen synthase kinase-3β in the inhibition of tumor necrosis factor-α- And interleukin-1β -induced inflammatory gene expression. J. Biol. Chem. 281: 16985-16990.
28. Oksvold, M. P., C. B. Thien, J. Widerberg, A. Chantry, H. S. Huitfeldt, and W. Y. Langdon. 2003. Serine mutations that abrogate ligand-induced ubiquitination and internalization of the EGF receptor do not affect c-Cbl association with the receptor. Oncogene 22: 8509-8518.
29. Signoret, N., and M. Marsh. 2000. Analysis of chemokine receptor endocytosis and recycling. Methods Mol. Biol. 138: 197-207.
30. Mueller, A., E. Kelly, and P. G. Strange. 2002. Pathways for internalization and recycling of the chemokine receptor CCR5. Blood 99: 785-791.
31. Chen, L., G. D. Salinas, and X. Li. 2009. Regulation of serotonin 1B receptor by glycogen synthase kinase-3. Mol. Pharmacol. 76: 1150-1161.
32. Kurowska-Stolarska, M., A. Hueber, B. Stolarski, and I. B. McInnes. 2011. Interleukin-33: A novel mediator with a role in distinct disease pathologies. J. Intern. Med. 269: 29-35.
33. Martinez-Moczygemba, M., D. P. Huston, and J. T. Lei. 2007. JAK kinases control IL-5 receptor ubiquitination, degradation, and internalization. J. Leukoc. Biol. 81: 1137-1148.
34. Jacobs, K. M., S. R. Bhave, D. J. Ferraro, J. J. Jaboin, D. E. Hallahan, and D. Thotala. 2012. GSK-3β: A bifunctional role in cell death pathways. Int. J. Cell Biol. 2012: 930710.
35. Kerkela, R., L. Kockeritz, K. Macaulay, J. Zhou, B. W. Doble, C. Beahm, S. Greytak, K. Woulfe, C. M. Trivedi, J. R. Woodgett, et al. 2008. Deletion of GSK-3β in mice leads to hypertrophic cardiomyopathy secondary to cardiomyoblast hyperproliferation. J. Clin. Invest. 118: 3609-3618.
36. Taelman, V. F., R. Dobrowolski, J. L. Plouhinec, L. C. Fuentealba, P. P. Vorwald, I. Gumper, D. D. Sabatini, and E. M. De Robertis. 2010. Wnt signaling requires sequestration of glycogen synthase kinase 3 inside multivesicular endosomes. Cell 143: 1136-1148.
37. Pálfy, M., A. Reményi, and T. Korcsmáros. 2012. Endosomal crosstalk: meeting points for signaling pathways. Trends Cell Biol. 22: 447-456.
38. ter Haar, E., J. T. Coll, D. A. Austen, H. M. Hsiao, L. Swenson, and J. Jain. 2001. Structure of GSK3β reveals a primed phosphorylation mechanism. Nat. Struct. Biol. 8: 593-596.
39. Hémar, A., A. Subtil, M. Lieb, E. Morelon, R. Hellio, and A. Dautry-Varsat. 1995. Endocytosis of interleukin 2 receptors in human T lymphocytes: distinct intracellular localization and fate of the receptor α, β, and γ chains. J. Cell Biol. 129: 55-64.
40. Gorbea, C., G. Pratt, V. Ustrell, R. Bell, S. Sahasrabudhe, R. E. Hughes, and M. Rechsteiner. 2010. A protein interaction network for Ecm29 links the 26 S proteasome to molecular motors and endosomal components. J. Biol. Chem. 285: 31616-31633.
41. Cross, D. A., D. R. Alessi, P. Cohen, M. Andjelkovich, and B. A. Hemmings. 1995. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378: 785-789.
42. Dudek, H., S. R. Datta, T. F. Franke, M. J. Birnbaum, R. Yao, G. M. Cooper, R. A. Segal, D. R. Kaplan, and M. E. Greenberg. 1997. Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science 275: 661-665.
43. Bhat, R. V., J. Shanley, M. P. Correll, W. E. Fieles, R. A. Keith, C. W. Scott, and C. M. Lee. 2000. Regulation and localization of tyrosine 216 phosphorylation of glycogen synthase kinase-3β in cellular and animal models of neuronal degeneration. Proc. Natl. Acad. Sci. USA 97: 11074-11079.
44. John, J. K., K. H. Paraiso, V. W. Rebecca, L. P. Cantini, E. V. Abel, N. Pagano, E. Meggers, R. Mathew, C. Krepler, V. Izumi, et al. 2012. GSK3β inhibition blocks melanoma cell/host interactions by downregulating N-cadherin expression and decreasing FAK phosphorylation. J. Invest. Dermatol. 132: 2818-2827.
45. Bianchi, M., S. De Lucchini, O. Marin, D. L. Turner, S. K. Hanks, and E. Villa-Moruzzi. 2005. Regulation of FAK Ser-722 phosphorylation and kinase activity by GSK3 and PP1 during cell spreading and migration. Biochem. J. 391: 359- 370.
46. Macagno, J. P., J. Diaz Vera, Y. Yu, I. MacPherson, E. Sandilands, R. Palmer, J. C. Norman, M. Frame, and M. Vidal. 2014. FAK acts as a suppressor of RTKMAP kinase signalling in Drosophila melanogaster epithelia and human cancer cells. PLoS Genet. 10: e1004262.
47. Sweet, M. J., B. P. Leung, D. Kang, M. Sogaard, K. Schulz, V. Trajkovic, C. C. Campbell, D. Xu, and F. Y. Liew. 2001. A novel pathway regulating lipopolysaccharide-induced shock by ST2/T1 via inhibition of Toll-like receptor 4 expression. J. Immunol. 166: 6633-6639.
48. Wieland, C. W., G. J. van der Windt, S. Florquin, A. N. McKenzie, and T. van der Poll. 2009. ST2 deficient mice display a normal host defense against pulmonary infection with Mycobacterium tuberculosis. Microbes Infect. 11: 524- 530.
49. Hayakawa, H., M. Hayakawa, A. Kume, and S. Tominaga. 2007. Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. J. Biol. Chem. 282: 26369-26380.
50. Mitra, S. K., and D. D. Schlaepfer. 2006. Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr. Opin. Cell Biol. 18: 516-523.
51. Garcea, G., M. M. Manson, C. P. Neal, C. J. Pattenden, C. D. Sutton, A. R. Dennison, and D. P. Berry. 2007. Glycogen synthase kinase-3β: A new target in pancreatic cancer? Curr. Cancer Drug Targets 7: 209-215.